AI drug discovery platform that identifies parasite-derived proteins to develop next-generation autoimmune therapies.
Ditto Bio uses AI to analyze proteins from parasites—viruses, ticks, and worms—that have evolved over millions of years to modulate the human immune system, identifying candidates for next-generation autoimmune therapies. The platform runs a full design-build-test-learn cycle combining computational biology with experimental validation. The founding team of PhD scientists from UCSF, UCSD, and UC Berkeley has identified thousands of promising protein candidates with therapeutic potential. Ditto Bio is a product of Ditto Biosciences.